THTX Theratechnologies Inc: רווח למניה בשנים עשר החודשים האחרונים

Diversification of the immunological drug portfolio has reduced Theratechnologies Inc. (THTX) dependence on single patents, as confirmed by earnings per share over the last four quarters, where the figure remains at -0.20. This has strengthened the company's authority in treating rare metabolic disorders and HIV. Business stability is further complemented by strict compliance with environmental standards during the disposal of biomaterials.
פילוחים אנליטיים ודוחות נתונים של חברת Theratechnologies Inc. (THTX)

Automating the synthesis of HIV drugs at Theratechnologies Inc. (THTX) requires significant investment, making an analysis of the business's ability to generate returns above the cost of capital critically important. This metric aggregates trailing twelve-month net income, adjusted for share issuance, which eliminates the impact of one-off transactions. The declining trajectory of net income per share over the last 12 months signals a revaluation of the asset.